newsabemaciclibbreast cancer
Neoadjuvant Abemaciclib plus Letrozole: A Potential Chemotherapy-Sparing Strategy in Select HR+/HER2- Breast Cancers?
By MedXY|Jan 11, 2026
The CARABELA trial suggests that while neoadjuvant abemaciclib plus letrozole did not meet the threshold for similarity to chemotherapy in highly proliferative HR+/HER2- breast cancer, it remains a viable alternative for patients with lower
